Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Bevacizumab + Trifluridine-tipiracil hydrochloride |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Bevacizumab | Avastin | VEGF Antibody 17 VEGFR Inhibitor (Pan) 36 | Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov). | |
| Trifluridine-tipiracil hydrochloride | Lonsurf | TAS-102|TAS102|TAS 102|S 95005|S95005|S-95005 | Lonsurf (trifluridine/tipiracil hydrochloride) is an oral combination comprised of TFT and a thymidine phosphorylase inhibitor, which can result in DNA fragmentation thereby preventing angiogenesis and tumor growth (PMID: 29226002). Lonsurf (trifluridine/tipiracil hydrochloride) is FDA-approved for use in patients with colorectal cancer, gastric or gastroesophageal junction adenocarcinoma, and in combination with Avastin (bevacizumab) in patients with previously-treated metastatic colorectal cancer (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05007132 | Phase II | Bevacizumab + Trifluridine-tipiracil hydrochloride Panitumumab + Trifluridine-tipiracil hydrochloride | Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | Recruiting | DEU | 0 |
| NCT07071844 | Phase II | Bevacizumab + Trifluridine-tipiracil hydrochloride | BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients (BETWEEN) | Not yet recruiting | FRA | 0 |
| NCT05029882 | Phase I | Bevacizumab + Telisotuzumab adizutecan Telisotuzumab adizutecan Bevacizumab + Trifluridine-tipiracil hydrochloride | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | Active, not recruiting | USA | POL | ISR | FRA | ESP | AUS | 4 |
| NCT06887218 | Phase II | Fluorouracil + Leucovorin + Regorafenib Bevacizumab + Trifluridine-tipiracil hydrochloride | 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer | Recruiting | USA | 0 |
| NCT04737187 | Phase III | Bevacizumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride | Phase III Study of Trifluridine/Tipiracil in Combination With Bevacizumab vs Trifluridine/Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT) | Completed | USA | POL | ITA | HUN | FRA | ESP | DNK | DEU | BRA | BEL | AUT | 3 |
| NCT06856837 | Phase II | Fruquintinib + Tislelizumab Bevacizumab + Trifluridine-tipiracil hydrochloride | - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases | Recruiting | DEU | AUT | 0 |
| NCT07525206 | Phase III | Bevacizumab + Telisotuzumab adizutecan Bevacizumab + Trifluridine-tipiracil hydrochloride | A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer (AndroMETa-CRC) | Recruiting | BEL | 3 |
| NCT02654639 | Phase II | Bevacizumab + Trifluridine-tipiracil hydrochloride | Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer | Terminated | USA | 0 |
| NCT07549412 | Phase III | M9140 Bevacizumab + M9140 Bevacizumab + Trifluridine-tipiracil hydrochloride | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) | Recruiting | USA | AUS | 0 |
| NCT06607458 | Phase II | Bevacizumab + Trifluridine-tipiracil hydrochloride Bevacizumab + Melphalan + Trifluridine-tipiracil hydrochloride | Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease (DEL-LIVER) | Recruiting | USA | TUR | NLD | ITA | ESP | DEU | CZE | 1 |
| NCT07527858 | Phase II | GS-1811 Bevacizumab + Trifluridine-tipiracil hydrochloride GS-1811 + Nivolumab Bevacizumab + GS-1811 + Trifluridine-tipiracil hydrochloride | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer | Recruiting | USA | AUS | 0 |
| NCT07381764 | Phase II | Cetuximab + Irinotecan Bevacizumab + Trifluridine-tipiracil hydrochloride | ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer" (ROMANCE - GOIM) | Not yet recruiting | ITA | 0 |
| NCT06522919 | Phase II | Bevacizumab + Trifluridine-tipiracil hydrochloride Pembrolizumab | Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer (CombiCoR-Vax) | Recruiting | ITA | 0 |